CM orders CID probe into Mangaluru police firing

Bengaluru, May 17: At least 54 new COVID-19 positive cases have emerged since last evening, raising Karnataka's tally to 1,146, a health official said today.

Among the 1,146 cases, 611 are active and isolated in designated hospitals across the state, 497 patients got discharged and 37 died of the virus.

Of the new cases, Mandya district alone reported 22 cases, followed by 10 in Kalaburgi, 6 in Hassan, 4 in Dharward, 3 each in Kolar and Yadgir, 2 each in Dakshina Kannada and Shivamogga and 1 each in Udupi and Shivamogga.

New Cases Reported: 54
Total Active Cases: 611
Total Discharges: 497
Total Covid Deaths: 37
Death of Covid +ve patient due to Non-Covid cause: 1
Total Positive Cases: 1146

Bengaluru, Apr 1: Karnataka Health Minister B Sriramulu on Wednesday said that 200 people, out of 342 from the state who had attended the religious gathering at Markaz building in Delhi's Nizamuddin area, have been quarantined.

"200 people including four from Bengaluru and five from Belgaum, who participated in Tablighi Jamaat (in Delhi's Nizamuddin), have been quarantined. Total 342 people from Karnataka had attended the event," Sriramulu told reporters here.

The gatherings organised by the Tablighi Jamaat at the Markaz building in Nizamuddin came into the spotlight after multiple coronavirus cases were confirmed amongst those who attended the event held in March.
Twenty-four cases were reported from the national capital alone, apart from Telangana, the union territory of Andaman and Nicobar Islands amongst others.

The minister had earlier said that Bengaluru Urban and Mysuru have been identified among the prime 25 COVID-19 hotspots in the country.
Chikkaballapur, since the last fourteen days, has been emerging as another hotspot, according to Sriramulu.

The total number of coronavirus cases in India has risen to 1,637 after 240 new cases were reported in the country, according to the Ministry of Health and Family Welfare, on Wednesday.

The total number of active cases rose to 1466 in the country, while 132 people have been cured and discharged after receiving treatment, as of 9 am.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.